Sun Pharma
Sun Pharma has been recognized as one of the top 5% of pharmaceutical companies globally, featured in the S&P Global Sustainability Yearbook 2025, solidifying its commitment to environmental, social, and governance practices.
Sun Pharmaceutical Industries Limited, a global pharmaceutical company, has been included in the prestigious S&P Global Sustainability Yearbook 2025, recognizing its commitment to environmental, social, and governance (ESG) principles. This achievement places Sun Pharma in the top 5% of pharmaceutical companies assessed globally for the yearbook.
The S&P Global Sustainability Yearbook 2025 aims to highlight companies that demonstrate strengths in corporate sustainability within their respective industries. This recognition validates Sun Pharma’s efforts to integrate ESG principles into its business strategy, focusing on initiatives that benefit the environment, society, and its stakeholders.
Dilip Shanghvi, Chairman and Managing Director of Sun Pharma, emphasized the company’s dedication to sustainable outcomes, stating, “Sustainability is an integral part of our way of doing business, and we are committed to aligning our strategy with universal ESG principles and advancing societal goals.”
The S&P Global Corporate Sustainability Assessment (CSA) 2024 evaluated over 7,690 companies globally, with 780 companies qualifying for inclusion in The Sustainability Yearbook 2025. This achievement is a testament to Sun Pharma’s commitment to ESG principles and its ongoing efforts to make a positive impact on the environment, society, and its stakeholders.
As a leading pharmaceutical company, Sun Pharma’s inclusion in the S&P Global Sustainability Yearbook 2025 underscores its commitment to sustainability and its role in shaping a better future for all stakeholders. By prioritizing ESG principles, the company is demonstrating its dedication to responsible business practices, promoting a healthier and more sustainable world.
Sun Pharma and Lupin’s US operations face a setback as they recall products from the market, impacting operations and potentially disrupting patient care.
Sun Pharma and Lupin, two major pharmaceutical companies in India, have initiated a voluntary recall of several products from the US market. The recall was initiated by the US Food and Drug Administration (FDA) due to alleged concentration variations in some lots of their products.
Sun Pharma, one of the largest generic drug makers in the world, has recalled 14 products due to the presence of a potential issue in their manufacturing process. The recalled products, including anti-inflammatory, anti-diabetic, and antibiotic treatment medications, were manufactured at one of Sun Pharma’s facilities in India. The company is recalling these products from the US market to ensure that patients receive high-quality medicines.
Lupin, another leading Indian generic drug maker, has also initiated a recall of 24 products due to a potential manufacturing issue. The recalled products include treatments for high blood pressure, cholesterol, and respiratory conditions. The FDA has identified a quality product deviation in some lots of these products, which may have resulted in incorrect concentrations of active pharmaceutical ingredients.
In both cases, the affected products are being recalled to ensure that patients receive the correct doses of medication and to prevent any potential harm. The FDA is working closely with both companies to ensure that the recalled products are removed from the market and that appropriate corrective actions are taken to prevent similar issues in the future.
The recalls are a testament to the importance of robust quality control measures in pharmaceutical manufacturing. The FDA’s vigilance in identifying potential issues and working with companies to correct them helps to ensure the safety and efficacy of medications in the US market. The recalls are also a reminder to consumers and healthcare professionals to stay vigilant and report any concerns about the quality or effectiveness of medications to the FDA.
Overall, the recalls highlight the need for pharmaceutical companies to maintain high-quality manufacturing standards and for healthcare professionals to be aware of potential issues with certain products. As the demand for affordable and effective medications continues to grow, it is essential for pharmaceutical companies to prioritize quality and for regulatory agencies to closely monitor and address any potential issues.
Will Sun Pharma carve out distinct business segments? CEO Dilip Shanghvi weighs in at ET Now’s Global Business Summit 2025.
At the ET NOW Global Business Summit 2025, Dilip Shanghvi, the Managing Director of Sun Pharma, was asked if the company would split its business into different verticals. Shanghvi responded by reiterating the company’s strategy to maintain its strengths and focus on delivering high-quality and affordable medicines to patients.
Shanghvi stated that Sun Pharma has a strong presence across the globe, with a diverse portfolio of products, including generic and specialty pharmaceuticals, biotechnology, and research materials. He mentioned that the company has adopted a multi-layered approach to manage its business, with separate divisions for different geographies and product categories.
However, Shanghvi clarified that the company has no immediate plans to split its business into separate verticals. He emphasized that Sun Pharma’s structure is designed to enable the company to leverage its global presence, expertise, and scale to deliver a diverse range of products and services to patients worldwide.
Shanghvi also highlighted the importance of the company’s strategy to develop internally and in-licensed products, particularly in emerging areas such as biosimilars, gene therapies, and cell and gene editing. He noted that Sun Pharma is well-positioned to leverage its strengths in these areas to deliver innovative and effective treatments to patients.
In response to a question about the company’s plans to increase its presence in high-value therapeutic areas, Shanghvi mentioned that Sun Pharma is focused on developing its capabilities in areas such as neuroscience, renal, and cardiovascular, where there is a growing need for innovative treatments. He emphasized the company’s commitment to investing in research and development to develop new and innovative products that address these unmet medical needs.
In conclusion, Shanghvi reiterated that Sun Pharma’s strategy is centered around delivering high-quality and affordable medicines to patients, and the company’s structure is designed to support its global presence, expertise, and product range. He expressed confidence in the company’s ability to continue to deliver value to its shareholders and patients while pursuing its vision to make a meaningful difference in the lives of millions of people worldwide.
Dilip Shanghvi, Founder and Managing Director of Sun Pharmaceutical Industries, underscores the importance of ‘Discover’ and ‘Make in India’ initiatives to foster innovation in the pharmaceutical sector.
India has emerged as a significant player in the global pharmaceutical industry, supplying high-quality medicines to over 200 countries and ranking third in production volume and 14th in value. With its strong manufacturing base, digital capabilities, and demographic advantage, India has the potential to become a global hub for life-sciences innovation. However, Indian companies, unlike global counterparts, allocate only 6-8% of their revenues to Research and Development (R&D), highlighting the need for a stronger focus on drug discovery.
Sun Pharma, a leading Indian pharmaceutical company, has made significant investments in building a portfolio of innovative medicines, including the $500-million product, Ilumya, for plaque psoriasis. With a focus on developing a global pipeline of patented products, Sun Pharma is centered on three therapeutic areas: dermatology, ophthalmology, and onco-dermatology, with seven new molecules in clinical trials.
Other Indian pharmaceutical companies are also actively working on new molecules, with over 20 in various stages of clinical development. Successfully bringing these innovative medicines to market will generate visibility and value for Indian companies, fostering a virtuous cycle and attracting further investment in R&D.
India’s “Make in India” initiative is a positive step, but “Discover and Make in India” will drive long-term sustainable growth, global competitiveness, and improved patient outcomes. As India drives the next wave of pharmaceutical innovation, it can ensure that life-saving medicines are not only discovered here but also made widely available worldwide. The future of healthcare is not just about breakthroughs in science but about ensuring those innovations reach the people who need them most.
Dilip Shanghvi, Founder and Managing Director of Sun Pharmaceutical Industries, will discuss how India can drive the next wave of pharmaceutical innovation at the ET NOW Global Business Summit 2025, highlighting the potential for Indian companies to discover and develop innovative medicines that can be made available globally at a lower cost, improving access to treatments and supporting global healthcare systems.
Sun Pharma and Philogen announce successful completion of patient enrollment in their Phase III clinical trial for Soft Tissue Sarcoma treatment.
Pharma and Philogen have successfully completed patient enrollment for their Phase III clinical trial on Soft Tissue Sarcoma treatment. Soft tissue sarcoma refers to a category of cancers affecting soft tissues within the body such as fat, muscle, deep skin tissues and other connective tissue. For patients with poor prognosis, metastatic soft tissue sarcoma provides limited treatment options and poor median survival rates resulting in a low five-year OS (overall survival) rate approximately 15.
The Phase III trial, currently under investigation as an open label study, entails assessing the primary efficacy endpoint OS. The subjects participating in this study are provided with either treatment consisting of Doxorubicin with or without Fotivda, a product candidate developed for treatment of ovarian and breast malignancies. With regards to side effects, commonly experienced adverse reaction categories include rash, nausea vomiting, fatigue muscle pain, insomnia and constipation.
Sun Pharma to fork out a record Rs 1,602 crore penalty, after emerging as the top company in a list of six major pharma firms currently under tax scanner.
Sun Pharma, one of India’s largest drug manufacturers, has been directed to pay a penalty of Rs 1,602 crore (approximately $220 million) to the Indian government. This comes as part of a broader crackdown on tax evasion by several top drug companies in the country. According to a report, the company’s tax demand was made following an investigation by theIncome Tax (I-T) department, which found irregularities in the company’s tax returns.
Sun Pharma is just one of six major drug companies being targeted in the tax scrutiny, which is a significant move by the government to crack down on tax evasion. The other companies include Dr. Reddy’s Laboratories, Lupin Ltd, Cadila Healthcare, Cipla Ltd, and Glenmark Pharmaceuticals. All of these companies are among the top 10 drug makers in the country.
The crackdown is based on alleged violations of the Income Tax Act, the Companies Act, and other laws. The I-T department claims that these companies had understated their taxable income by reclassifying revenues, misstating expenditure, and manipulating accounts. The tax authority has also accused them of failing to disclose information on loan transactions, capital gains, and foreign exchange earnings.
The I-T department’s action is a major development in the country’s pharmaceutical industry, which has been reeling from the impact of recent regulatory changes and tough competition from generic drug makers. While the exact timing of the tax demand is unclear, it is widely believed to be in response to a hint given by the government in 2019 that it would become stricter in enforcing tax laws.
It is worth noting that the companies have the right to appeal against the tax demand and the I-T department’s findings. While some of these companies have already appealed, others have chosen to contest the demand through legal means. The outcome of this high-stakes battle will be keenly watched by investors, taxpayers, and the pharmaceutical industry as a whole.
Meet Rohan Singh, a highly influential executive with a significant role to play in the operations of India’s leading conglomerate, valued at over Rs 422,000 crore, whose father, Rajesh Singh, played a pivotal role in shaping his career.
Aalok Shanghvi, the son of Sun Pharma’s Managing Director Dilip Shanghvi, has been appointed as the Chief Operating Officer (COO) of the company, which has a market capitalization of Rs 422,000 crore. Aalok joined Sun Pharma in 2006 and has held various roles in marketing, R&D, project management, purchase, and communications. His father, Dilip Shanghvi, is one of the richest pharma company owners in India, with a net worth of USD 27.6 billion.
Aalok holds a graduation degree in Cellular and Molecular Biology from the University of Michigan, US. He has also worked as the Head of Emerging Markets, a position he took up in 2014, which covers 80 countries across Africa, the Middle East, Asia-Pacific, Eastern Europe, the Commonwealth of Independent States, and Latin America.
Sun Pharma has recently announced its Q3 results, which show a 15% year-on-year increase in revenue, reaching Rs 2,903 crore. The company also recorded an exceptional item of Rs 316 crore during this period. According to Dilip Shanghvi, Chairman and MD of Sun Pharma, the company’s performance in the quarter showed all-round improvement, with product sales in Global Specialty crossing 1/5th of overall sales.
Sun Pharma, one of the first Indian pharmaceutical companies to invest in research, has grown from humble beginnings in the 1980s to become one of the largest generic pharmaceutical companies worldwide and the largest pharmaceutical company in India. With Aalok Shanghvi’s appointment as COO, the company is keen to build on its success and continue to drive growth and innovation in the pharma industry.
Sun Pharma’s net profit surges 15% to ₹2,903 crore in Q3, marking a strong performance in the latest quarter.
Sun Pharma, a leading multinational pharmaceutical company, has reported a 15% increase in its net profit for the third quarter (Q3) of the current financial year. The company’s net profit has risen to Rs 2,903 crore (approximately $395 million USD) for the quarter ended December 31, 2022.
This significant growth in net profit is attributed to the company’s focused efforts to strengthen its product portfolio, expand its presence in key markets, and optimize its cost structure. Sun Pharma has also made strategic investments in research and development (R&D), procurement, and marketing to drive future growth.
The company’s revenue has also shown a strong growth of 8% year-on-year, reaching Rs 14,127 crore (approximately $1.9 billion USD) for the quarter. The increase in revenue is driven by a combination of factors, including the company’s investments in new products, expansion into emerging markets, and strong demand for its existing medicines.
Sun Pharma’s strong performance is also driven by its ability to manage costs effectively, with operational expenses growing at a lower rate than revenue. The company’s focus on operational efficiency, including cost savings initiatives, has helped to offset the impact of inflation and other macroeconomic challenges.
The company’s growth has been driven by its presence in key markets, including the United States, India, and the Middle East. Its strong sales performance in these markets, coupled with new product launches and an expanding presence in emerging markets, has contributed to the growth.
In its release, the company credited its employees for the success, stating that “the strong performance in the quarter is a testament to the hard work and dedication of our employees, who continue to deliver exceptional results despite the challenging macroeconomic environment.”
Overall, Sun Pharma’s Q3 results demonstrate the company’s ability to navigate the complex global pharmaceutical industry and achieve strong growth through strategic investments, operational efficiency, and a robust product portfolio. With a strong balance sheet and a relentless focus on innovation, Sun Pharma is well-positioned to continue its growth momentum in the coming quarters.
Sun Pharma Labs Receives Approval from CDSCO Panel to Conduct Phase-III Clinical Trial of Semaglutide Solution for Injection
Sun Pharma Labs, a leading pharmaceutical company, has received approval from the Central Drugs Standard Control Organization (CDSCO) to conduct Phase-III clinical trials in India for its new semi-synthetic peptide, semaglutide solution for injection. This is a significant milestone in the company’s efforts to develop treatments for diabetes and related conditions.
Semaglutide is a medication used to help manage type 2 diabetes and has been approved by regulatory authorities in many countries, including the US and Europe. The injection is designed to help regulate blood sugar levels by mimicking the effects of natural hormones that help insulin production in the body. Sun Pharma Labs’ version of semaglutide is a semi-synthetic peptide that is similar to the original drug but is produced using a different manufacturing process, which is more cost-effective and scalable.
The company has designed the Phase-III clinical trial to assess the efficacy and safety of its semi-synthetic peptide in a larger patient population. The trial will involve approximately 200 patients with type 2 diabetes who will receive either the semi-synthetic peptide or a placebo treatment. The study will measures the reduction in HbA1c levels, a key indicator of blood sugar control, as well as other measures of safety and efficacy.
The approval from CDSCO is a significant milestone for Sun Pharma Labs, which plans to commercialize the product in India and other emerging markets. The company is expected to file for regulatory approval with the Indian drug regulator, the Central Drugs Standard Control Organization (CDSCO), after the completion of the Phase-III clinical trial.
Semaglutide has the potential to address the unmet needs of millions of patients with type 2 diabetes in India and other emerging markets. The company’s semi-synthetic peptide is designed to be more affordable and accessible than the branded version, making it a potential game-changer for patients who need more effective and sustainable treatment options. With this approval, Sun Pharma Labs is one step closer to making this innovative therapy available to patients in India and other developing countries.
The pharma industry is likely to experience a slow pace of profit expansion in the third quarter.
Pharmaceutical companies in India are expected to experience slower profit growth in the October-December 2024 quarter compared to the previous two quarters. According to analysts, sales growth is projected to be around 10-12% and earnings before interest, taxes, depreciation, and amortisation (EBITDA) growth of 13-15%. The growth momentum is expected to slow down due to pricing pressures and a high base effect.
Large companies such as Dr Reddy’s Laboratories (DRL) and Sun Pharma are expected to contribute to the sales growth, with DRL projected to achieve over 10% growth in its India business. Mid-sized companies like JB Pharma, Torrent Pharma, and Mankind Pharma are likely to outperform with 11-13% year-on-year (YoY) growth, driven by their chronic portfolios.
In contrast, Cipla and Zydus are expected to report relatively weaker growth of 6-8% YoY due to supply constraints and base effects. The US generics segment is projected to remain flat due to price erosion and limited significant launches.
Overall, EBITDA is expected to grow by up to 15% YoY, but margins are expected to remain flat. Cipla and DRL are likely to face margin contraction, while Sun Pharma, Lupin, and Divi’s Laboratories are expected to report strong margin expansion.
The performance of key pharma players will be closely monitored by investors, particularly with respect to their outlook and commentary on margins. Updates on DRL approval timelines for large products in the US, Biocon’s outlook following the clearance of its facilities for biosimilars, and Aurobindo Pharma’s progress towards breakeven for its Penicillin G capacity will also be crucial.
Taro Pharma to fully acquire and own Antibe Therapeutics, solidifying its presence in the pharmaceutical industry.
India’s Sun Pharmaceutical Industries, a subsidiary of Taro Pharmaceuticals, has entered into an agreement to acquire 100% stake in Antibe Therapeutics, a clinical-stage biotechnology company based in Ontario, Canada. The acquisition is a part of Sun Pharma’s strategy to expand its pharmaceutical and healthcare portfolio, particularly in the area of pain and inflammation management. Antibe Therapeutics specializes in developing novel drugs focused on reducing pain and inflammation. The acquisition is subject to a “reverse vesting order” and approval from the Ontario Superior Court of Justice (Commercial List) and is expected to be closed by March 7, 2025.
This deal is part of Sun Pharma’s efforts to strengthen its presence in the pharmaceutical and healthcare space. Antibe Therapeutics has a strong pipeline of products, which will complement Sun Pharma’s existing portfolio. The acquisition will also provide Sun Pharma with a foothold in the Canadian market, giving the company access to a new market and customer base.
The acquisition of Antibe Therapeutics is significant for Sun Pharma, as it demonstrates the company’s commitment to expanding its presence in the global pharmaceutical industry. The deal is also a strategic one for Antibe Therapeutics, as it will provide the company with the resources and expertise needed to bring its products to market. Overall, the acquisition is a win-win for both companies, and it will be interesting to see how it unfolds in the coming months.
India’s Sun Pharma set to acquire Canadian biotech company Antibe
Here is a summary of the content in 400 words:
Antibe Therapeutics, a Canadian biotech company that has been struggling since last year, has reached a deal to be acquired by Taro Pharmaceutical, a subsidiary of Sun Pharma, for an all-cash agreement. The takeover is subject to approval by the Ontario Superior Court of Justice, and the valuation of the transaction will be revealed after completion, due to receivership rules. Antibe, which has been under a cease trade order since July 24, has failed to file financial statements and secure investor backing. The company had been developing a lead drug, otenaproxesul, an anti-inflammatory pill designed to relieve acute pain. However, clinical trials were stalled due to regulatory issues, including a clinical hold by the US FDA and disputes with a China-based partner. Antibe aimed to develop the drug for treating acute pain after seeing liver concerns with chronic use in osteoarthritis.
The company has a pipeline of other drugs utilizing its hydrogen-sulfide platform, including an undisclosed pain therapy and early research programs for inflammatory bowel disease. However, the financial filing disclosed that the acquiring company, Taro, does not include “certain assets and liabilities” in the offer, which may be transferred to a residual Antibe company, leaving uncertainty as to which assets will be preserved. The company’s financial plight has been troubled by a receiver’s order regarding a licensing deal with Nuance Pharma, demanding a $20 million refund plus interest and expenses. The pending acquisition by Taro Pharmaceutical adds a new uncertainty to Antibe’s future after a tumultuous year. If approved, Taro will take ownership of Antibe’s assets in a deal intended to close on March 7.